Can-Fite BioPharma (CANF) EBIT Growth (1y) (2015 - 2023)
Can-Fite BioPharma (CANF) EBIT Growth (1y) (2015 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.14% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 269.85% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,528.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -336.63% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -36.55% |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -55.16% |
| Sep 30, 2023 | 27.52% |
| Jun 30, 2023 | 13.82% |
| Mar 31, 2023 | -14.43% |
| Dec 31, 2022 | 70.66% |
| Sep 30, 2022 | 26.70% |
| Jun 30, 2022 | 33.93% |
| Mar 31, 2022 | -9.17% |
| Dec 31, 2021 | -13.37% |
| Sep 30, 2021 | -41.59% |
| Jun 30, 2021 | 18.22% |
| Mar 31, 2021 | 49.23% |
| Dec 31, 2020 | 22.95% |
| Sep 30, 2020 | 11.18% |
| Jun 30, 2020 | 39.34% |
| Mar 31, 2020 | -349.91% |
| Dec 31, 2019 | -84.22% |
| Sep 30, 2019 | -533.39% |
| Jun 30, 2019 | -22.81% |
| Mar 31, 2019 | 7.75% |